Protalex, Inc.
6
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
50.0%
3 terminated/withdrawn out of 6 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
Role: lead
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
Role: lead
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
Role: lead
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
Role: lead
Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis
Role: lead
Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers
Role: lead
All 6 trials loaded